- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Yale Cancer Center | Strategic Alliance Partners
Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
Latest from Yale Cancer Center
Dr Rimm on the Effect of Inaccurate HER2 IHC Testing for Patients With Breast Cancer
November 27, 2024
Video
David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.
Dr Rimm on the Utility and Shortcomings of HER2 IHC Testing in Breast Cancer
November 18, 2024
Video
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
November 14, 2024
Video
Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC
November 09, 2024
Article
David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.
Dr Rimm on Limitations With IHC Testing in HER2-Low and HER2-Ultralow Breast Cancer
October 23, 2024
Video
David Rimm, MD, discusses the current limitations of immunohistochemistry diagnostic kits for HER2-low and HER2-ultralow breast cancer.
FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL
October 17, 2024
Podcast
Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.
TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors
October 15, 2024
Article
Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
September 26, 2024
Podcast
Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.
Clinical Scenario: Metastatic EBV-Positive NPC
September 25, 2024
Video
The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.
Dr Rimm on the Limitations of HER2 IHC Assays in Breast Cancer
September 19, 2024
Video
David Rimm, MD, PhD, discusses the limitations of current HER2 immunohistochemistry assays in breast cancer.
Clinical Scenario: Locally Recurrent NPC
September 18, 2024
Video
Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.
Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
September 18, 2024
Video
Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.
Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
September 11, 2024
Video
The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.
Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
September 11, 2024
Video
Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.
Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
September 04, 2024
Video
Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.
Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
September 04, 2024
Video
Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.
Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management
August 29, 2024
Podcast
Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.
Value of PD-L1 Biomarker in NPC
August 28, 2024
Video
A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.
Overview of the JUPITER and POLARIS-2 Trials
August 28, 2024
Video
Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.
Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC
August 26, 2024
Video
Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.